Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.19 Insider Own39.55% Shs Outstand36.43M Perf Week-4.70%
Market Cap26.72M Forward P/E- EPS next Y- Insider Trans-0.30% Shs Float33.20M Perf Month-21.06%
Income-43.27M PEG- EPS next Q- Inst Own3.90% Short Float4.45% Perf Quarter-61.08%
Sales0.00M P/S- EPS this Y- Inst Trans-34.96% Short Ratio0.57 Perf Half Y-84.65%
Book/sh0.19 P/B2.59 EPS next Y- ROA-125.99% Short Interest1.48M Perf Year-94.06%
Cash/sh0.37 P/C1.32 EPS next 5Y- ROE-257.84% 52W Range0.44 - 8.69 Perf YTD-61.39%
Dividend Est.- P/FCF- EPS past 5Y16.23% ROI-576.19% 52W High-94.40% Beta1.22
Dividend TTM- Quick Ratio1.47 Sales past 5Y0.00% Gross Margin- 52W Low9.33% ATR (14)0.07
Dividend Ex-Date- Current Ratio1.47 EPS Y/Y TTM20.39% Oper. Margin0.00% RSI (14)36.94 Volatility9.53% 8.92%
Employees18 Debt/Eq1.37 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q56.27% Payout- Rel Volume0.20 Prev Close0.49
Sales Surprise- EPS Surprise- Sales Q/Q- Earnings- Avg Volume2.58M Price0.49
SMA20-4.65% SMA50-40.02% SMA200-80.57% Trades Volume512,096 Change-0.39%
Date Action Analyst Rating Change Price Target Change
Jul-22-22Initiated Cantor Fitzgerald Overweight $7
Jan-15-21Initiated B. Riley Securities Buy $47
Apr-18-24 08:00AM
Apr-12-24 09:00AM
Mar-26-24 10:30AM
Mar-13-24 11:30AM
Mar-12-24 09:55AM
09:41AM Loading…
Mar-11-24 10:48AM
Mar-06-24 06:21PM
Mar-05-24 11:39AM
Mar-04-24 05:16PM
Mar-01-24 04:58PM
04:58PM Loading…
Feb-23-24 04:49PM
Feb-19-24 01:12PM
Feb-09-24 03:40PM
Feb-07-24 01:00PM
Feb-06-24 08:00AM
Jan-29-24 01:28PM
Jan-27-24 05:29AM
Jan-25-24 12:34PM
Jan-24-24 11:30AM
Jan-19-24 07:18PM
03:14PM Loading…
Jan-17-24 03:14PM
Jan-11-24 10:25AM
Jan-05-24 02:08PM
Dec-29-23 09:00AM
Dec-25-23 11:15AM
Dec-22-23 09:00AM
Dec-21-23 10:25AM
Dec-18-23 02:32PM
Dec-13-23 04:36PM
Dec-11-23 09:35AM
Dec-04-23 03:23PM
Nov-30-23 02:21PM
Nov-29-23 11:38AM
Nov-13-23 08:00AM
Nov-10-23 09:00AM
Nov-02-23 08:00AM
Oct-30-23 01:00PM
Oct-26-23 08:00AM
Oct-25-23 12:30PM
Oct-19-23 10:00AM
Sep-26-23 08:00AM
Sep-20-23 08:45AM
Sep-19-23 08:00AM
Sep-12-23 02:10PM
Sep-11-23 08:00AM
Sep-07-23 08:00AM
Aug-31-23 08:00AM
Aug-30-23 09:35AM
Aug-28-23 10:22AM
Aug-24-23 09:35AM
Aug-11-23 10:05AM
Jul-20-23 01:06PM
Jul-18-23 07:00AM
Jul-17-23 07:00AM
Jul-13-23 04:26PM
Jul-10-23 08:00AM
Jun-28-23 12:59PM
Jun-26-23 08:00AM
Jun-23-23 08:00AM
Jun-21-23 08:00AM
Jun-15-23 01:15PM
May-16-23 04:05PM
Apr-24-23 02:09AM
Apr-20-23 08:30AM
Apr-17-23 08:00AM
Mar-24-23 08:30AM
Mar-21-23 08:01AM
Mar-15-23 10:59AM
Mar-14-23 08:00AM
Mar-13-23 08:00AM
Mar-10-23 11:04AM
Mar-09-23 08:00AM
Mar-06-23 02:44PM
Mar-02-23 02:03PM
Feb-21-23 08:00AM
Jan-25-23 08:00AM
Jan-05-23 01:07PM
Jan-03-23 06:32AM
Dec-29-22 08:30AM
BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORLIN STEVEDirectorDec 01 '23Sale1.6975,680127,89946,358Dec 06 04:16 PM
DO CUONG VPresident & CEONov 30 '23Buy1.7810,00017,80068,759Dec 01 06:26 PM
GORLIN STEVEDirectorSep 05 '23Sale3.058,56026,10875,680Sep 07 06:20 PM
BERMAN RICHARD JDirectorAug 22 '23Sale3.5010,80537,82716,789Aug 24 08:33 PM
BERMAN RICHARD JDirectorJun 07 '23Sale5.815,98434,78223,210Jun 15 05:15 PM
BERMAN RICHARD JDirectorMay 22 '23Sale6.505,00032,50629,194Jun 15 05:15 PM